semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-99.0,  Allan-Herndon-Dudley Syndrome clinically relevant mutation in the MCT8 gene, resulting in the clinical phenotype of AHDS  Major illness or recent major surgery (within 4 weeks) unrelated to AHDS Patients who are participating in ongoing RCTs of therapeutic interventions (including clinical trials of investigational medicinal products) Known allergy to components in Triac tablets Patients that have any contra-indication for Triac treatment
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 10.0-18.0,  Polycystic Ovary Syndrome Abnormal Weight Gain Excess Weight Insulin Resistance Premature Adrenarche Type 2 Diabetes Mellitus Female Ages 10-18 yr Participating in the Go Girls! program With diagnoses of abnormal weight gain, excess weight, insulin resistance, PCOS, premature adrenarche, or type 2 diabetes mellitus  Known pregnancy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Hashimoto's Thyroiditis Newly diagnosed (within 1 year) Hashimoto's thyroiditis by positive serum anti-TPO antibody or anti-thyroglobulin antibody Euthyroid state by serum free T4 and TSH level within normal limit  Pregnant, planning pregnant within 1 year, or lactating women Renal insufficiency, abnormal liver function test Hematologic diseases: anemia, agranulocytosis, thrombocytopenia G6PD deficiency, porphyria cutaneous tarda Allergy to 4-aminoquinoline compounds Known retinopathy or visual field defect disorders Already receive immunosuppression therapy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Invasive Breast Cancer (Stage I-III) Ductal Carcinoma in Situ Lobular Carcinoma in Situ Lobular Carcinoma Fatigue Related to Cancer Treatment for Monitoring Phase Age ≥ 18 Diagnosis of: invasive breast cancer (stage I-III), ductal carcinoma in situ, lobular carcinoma in situ, lobular carcinoma Plan to receive radiation therapy for Randomization Phase Participants may have had prior breast surgery and/or chemotherapy Age ≥18 years. --Because no dosing or adverse event data are currently available on the use of naltrexone in cancer patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials Participants must have acceptable pre-treatment laboratory values as defined below total bilirubin within normal institutional limits AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal creatinine within normal institutional limits OR  for Monitoring Phase Suicidal ideation, as determined via PHQ-9 Non-English speaking for Randomization Phase Participants with major depressive disorder and/or suicidal ideation as determined by PHQ-9 Participants who are receiving any other investigational agents that might interact with study medication or influence the measurement of study outcomes Participants with known metastatic disease should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events History of allergic reactions attributed to compounds of similar chemical or biologic composition to naltrexone Participants who have used opioid-containing medications (including cough/cold medications containing codeine and/or antidiarrheals containing loperamide) in the past 2 weeks, or who are expected to require opioid-containing medications within the duration of the treatment period Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 7.0-17.0,  Puberty Hyperandrogenism Early and late pubertal girls with normal androgens Early and late pubertal girls with hyperandrogenemia All subjects will be girls from pre-puberty (Stage 1 breast development and pubic hair growth but at least 7 years old) to 7 years post menarche  Pregnancy Inability to comprehend what will be done during the study or why it will be done Hemoglobin <11.5 g/dL for non-African American subjects; Hemoglobin < 11.0 g/dL for African American subjects Persistently abnormal sodium, potassium, or bicarbonate (i.e., confirmed on repeat) Persistently elevated creatinine, hepatic transaminases, or alkaline phosphatase (i.e., confirmed on repeat) Total bilirubin > 1.5 times upper limit of normal (i.e., confirmed on repeat) Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; asthma requiring intermittent systemic corticosteroids; etc.) Untreated hypo or hyperthyroidism (reflected by persistently abnormal TSH values) Total testosterone > 200 ng/dl
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 6.0-17.0,  Obesity Insulin Resistance Vitamin D Deficiency age 6-17 years BMI > 95% for age serum 25-OH D level < or + to 25 ng/mL  BMI < 95% for age serum 25-OH D level > 25 ng/mL current Vitamin D supplementation > 400 IU/day anti-convulsant therapy, anti-hypertensive therapy, lipid lowering medication any medications that affect glucose metabolism (e.g., metformin, insulin) daily glucocorticoid therapy diabetes any disorders of bone or calcium metabolism hepatic or renal disease any malabsorptive disorder
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 2.0-17.0,  Epilepsy The following were applied in selecting patients for participation in the trial. Patient was eligible for entry into the baseline phase if he/she fulfilled the following at Visit 1 Written informed consent given by the parent(s)/guardian(s), and by the patient when appropriate Male or female patient aged between 2 and 17 years Body weight within the 10th and 90th percentiles, by age and sex A documented diagnosis of partial-onset seizures (simple or complex seizures with or without secondary generalisation), classified according to the International Classification of Epileptic Seizures Currently treated with 1 to 3 AEDs (any except OXC or CBZ), in a stable dosage regimen during at least 1 month prior to screening Good general health (apart from epilepsy) based on medical history and physical examination In case of a female patient, she was premenarchal, surgically sterile or presented a urine pregnancy test consistent with a non-gravid state and practiced an effective non-hormonal contraception method. At Visit 2, patient was eligible for entry into the Eslicarbazepine acetate treatment phase if he/she fulfilled the following At least 4 partial-onset seizures during the last 4 weeks of the baseline phase Brain CT scan or MRI that excluded rapidly progressive neurological diseases  Patient was not allowed for entry into the screening phase if he/she fulfilled the following at Visit 1 Primarily generalised epilepsy Clinically relevant medical condition, other than epilepsy History of status epilepticus in the last 3 months History of suicide attempt History of alcohol or drug abuse History of hypersensitivity or intolerance to OXC or CBZ Use of any investigational drug or participated in any clinical trial within the previous 2 months Patient and/or his/her caregiver(s) unlikely to co-operate with the requirements of the study If female, she was sexually active and of child-bearing potential and she did not use reliable contraception
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-20.0,  Nicotine Dependence, Other Tobacco Product Ages 18-20 years Able to read and write Cigarette smoker Use of e-cigarettes in the past 30 days  Seeking smoking cessation treatment Current/lifetime for dependence on another psychoactive substance -Daily use of alcohol or marijuana or use of any other drugs including cocaine, opiates, stimulants Regular use of psychoactive drugs including anxiolytics, antidepressants and other psychostimulants Current or past history of psychosis or other psychiatric diagnosis such as major depression Any significant current medical condition
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cushing Disease Clinical diagnosed Cushing's disease  Already received treatment in other hospital Ectopic Cushing's syndrome
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Preeclampsia Attendance at ANC clinic in a primary care facility in Kakamega north  Gestational age < 16 weeks Gestational age > 30 weeks Dietary or medicinal consumption of adequate calcium (according to the screening survey) Intention to leave study community before 8weeks from date of interview
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cystic Fibrosis Lung Disease Newly diagnosed patients with Cystic Fibrosis (CF). Diagnosis of CF: at least one of the following three international accepted is fulfilled: i) sweat chloride ≥ 60mEq/L and/or ii) 2 CF-causing mutations in the CFTR gene and/or iii) changes typical for CF in the transepithelial potential difference in nasal or rectal epithelium. 2. Age and mode of diagnosis Early diagnosed (ED): Initial diagnosis following CF-NBS or for other reasons in the first 4 months of life (in preterms corrected age of 4 months) after January 1st, 2006. Other reasons could be prenatal diagnostics, meconium ileus or positive family history Late diagnosed (LD): Diagnosed after the fourth month of life due to clinical symptoms; initial diagnosis after January 1st, 2006  All patients are excluded who themselves or whose parents do not want to participate or that withdraw from the study; or those in whom the diagnosis of CF is unsure. Further are: 1. Preterms <30th week of gestation 2. Longer period of mechanical ventilation in first 3 months of life 3. A significant medical disease or condition other than CF likely to interfere with the child's ability to complete the entire protocol 4. Previous major surgery except for meconium ileus or atresia of the intestine 5. Other major organ dysfunction, excluding pancreatic or hepatic dysfunction or another condition due to CF 6. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by investigator 7. Chronic lung disease other than CF (e.g. bronchopulmonary dysplasia) 8. History of adverse reaction to medication for sedation or known claustrophobia which lead to a displacement of the procedures in sedation until the child has recovered Clinically significant upper airway obstruction as determined by investigator (e.g. severe laryngomalacia, markedly enlarged tonsils, significant snoring, diagnosed obstructive sleep apnoea) Severe gastroesophageal reflux, defined as persistent frequent emesis despite anti-reflux therapy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-25.0,  Diffuse Intrinsic Pontine Glioma (DIPG) for Newly Diagnosed Patients with diffuse intrinsic pontine glioma (DIPG) Diagnosis: Patients with newly diagnosed DIPG, defined as tumors with a pontine epicenter and diffuse involvement of the pons who undergo a biopsy are eligible. Patients with disseminated disease are not eligible, and MRI of the spine must be performed if disseminated disease is suspected by the treating physician Enrollment within 28 days of the date of radiographic diagnosis Age ≤ 25 years Karnofsky score ≥ 50 for patients ≥ 16 years of age and Lansky score ≥ 50 for patients ≤15 years of age. Patients who are unable to walk because of paralysis but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score  Organ Function Requirements Adequate Bone Marrow Function Defined as Peripheral absolute neutrophil count (ANC) ≥ 1000/mm 3 Platelet count ≥ 100,000/mm 3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) Hemoglobin ≥ 8 g/dl (can be transfusion dependent)  for Newly Diagnosed Patients with DIPG Patients who are currently taking any anti-cancer directed therapy. Steroids are not considered anti-cancer therapy Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Female patients of childbearing potential must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Schizophrenia Metabolic Syndrome Vitamin D Deficiency • Men and women with a DSM-IV clinical diagnosis of Schizophrenia, Schizoaffective or Bipolar disorder to 65 years of age; male and female A willingness and ability to provide signed informed consent The subject should have been on quetiapine 100 mg or more for more than 12 weeks  Pregnant women 2. Subjects considered at high suicide risk based on the MINI Suicidality Module (> 17 points) 3. Unstable general medical condition or serious illness (e.g. death or hospitalization is anticipated within one year), poor kidney function or liver function (defined as laboratory values ≥ three times the upper limit of the normal), and seizure disorders except for childhood seizure disorders 4. Concurrent therapy with certain psychotropics is permitted, provided that the medication and dose have been stable for the past 90 days 5. Patients on concomitant treatment with clozapine and olanzapine are not permitted. 6. Patients on immunosuppressant medications or any orexigenic or anorexigenic drug 7. Patients on concomitant treatment with amphetamines and/ or methylphenidate 8. History of hypothyroidism or thyroxine therapy 9. Patients with a known condition or undergoing therapeutic measures that affects weight, including but not limited to: eating disorder, type I diabetes, hyperthyroidism, thyroxine therapy, Topamax therapy, and infectious diseases, such as HIV, hepatitis B, and hepatitis C 10. Active supplementation of vitamin D within the last 3 months
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-45.0,  Infants of Diabetic Mothers (understood to only abstemious women) 1. . Pregnant women expected to deliver between 37 and 41 weeks gestation (controls), and their babies 2. . Pregnant women expected to deliver between 37 and 41 weeks gestation who have class A1 diabetes mellitus, and their babies 3. . Pregnant women expected to deliver between 37 and 41 weeks gestation who have class A2 diabetes mellitus, and their babies 4. . Pregnant women expected to deliver between 37 and 41 weeks gestation who were diagnosed with diabetes mellitus prior to their pregnancy, and their babies  . Mothers who self-reported any alcohol or any illicit drug use during their pregnancy (and their babies) 2. . Mothers who had a positive drug screen at any point during their pregnancy (and their babies) 3. . Babies whose mothers suffered a placental abruption during their pregnancy. 4. . Babies whose mothers had inadequate prenatal care (defined as <3 prenatal clinic visits prior to admission for delivery) 5. . Non-English-speaking mothers 6. . Babies who pass meconium in utero. 7. . Babies born with multiple congenital anomalies or abdominal wall defects
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 17.0-40.0,  Diabetes Mellitus Undergraduate students in their final-year medicine clerkship at the University of the West Indies, who are within one year of starting supervised post-graduate employment (internship) Students who consent to participate in the study (voluntary participation only)  Students who refuse consent to participate in the study